These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2908627)

  • 1. Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins.
    Wawrzynczak EJ; Thorpe PE
    Cancer Treat Res; 1988; 37():239-51. PubMed ID: 2908627
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotoxins containing single-chain ribosome-inactivating proteins.
    Lambert JM; Blättler WA; McIntyre GD; Goldmacher VS; Scott CF
    Cancer Treat Res; 1988; 37():175-209. PubMed ID: 2908625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-toxin conjugation.
    Marsh JW; Srinivasachar K; Neville DM
    Cancer Treat Res; 1988; 37():213-37. PubMed ID: 2908626
    [No Abstract]   [Full Text] [Related]  

  • 4. Preparation of cytotoxic antibody-toxin conjugates.
    Cumber AJ; Wawrzynczak EJ
    Methods Mol Biol; 1998; 80():135-44. PubMed ID: 9664370
    [No Abstract]   [Full Text] [Related]  

  • 5. Kinetic analysis of cytotoxicity.
    Kim YW
    Cancer Treat Res; 1988; 37():405-15. PubMed ID: 2908636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
    Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
    Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotoxin therapy: assessment by animal models.
    Griffin TW; Morgan AC; Blythman HE
    Cancer Treat Res; 1988; 37():433-55. PubMed ID: 2908638
    [No Abstract]   [Full Text] [Related]  

  • 8. Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein alpha-sarcin from Aspergillus giganteus.
    Wawrzynczak EJ; Henry RV; Cumber AJ; Parnell GD; Derbyshire EJ; Ulbrich N
    Eur J Biochem; 1991 Feb; 196(1):203-9. PubMed ID: 2001699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxin preparation and testing in vitro.
    Frankel AE; Welsh PC; Withers DI; Schlossman DM
    Targeted Diagn Ther; 1988; 1():225-44. PubMed ID: 2979057
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
    Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
    J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activity of two immunotoxins composed of monoclonal antibody MoAb-16 and A-chain of ricin (MoAb-16-RTA) or A-chain of mistletoe lectin I (MoAb-16-MLIA).
    Paprocka M; Wiedłocha A; Walzel H; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1992; 40(3-4):223-7. PubMed ID: 1300987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotoxin enhancers.
    Casellas P; Jansen FK
    Cancer Treat Res; 1988; 37():351-69. PubMed ID: 2908632
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotoxins containing A-chain of mistletoe lectin I are more active than immunotoxins with ricin A-chain.
    Tonevitsky AG; Agapov II; Shamshiev AT; Temyakov DE; Pohl P; Kirpichnikov MP
    FEBS Lett; 1996 Aug; 392(2):166-8. PubMed ID: 8772196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins.
    Preijers FW
    Leuk Lymphoma; 1993 Mar; 9(4-5):293-304. PubMed ID: 8348066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic ribonuclease chimeras. Targeted tumoricidal activity in vitro and in vivo.
    Newton DL; Ilercil O; Laske DW; Oldfield E; Rybak SM; Youle RJ
    J Biol Chem; 1992 Sep; 267(27):19572-8. PubMed ID: 1527074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma.
    Rosenblum M
    Adv Pharmacol; 2004; 51():209-28. PubMed ID: 15464911
    [No Abstract]   [Full Text] [Related]  

  • 19. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
    Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of immunotoxins: current progress and future prospects.
    Wawrzynczak EJ
    Anticancer Drug Des; 1992 Oct; 7(5):427-41. PubMed ID: 1388633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.